GILEAD SCIENCES, INC. is 97.2x more valuable than Taysha Gene Therapies, Inc. by market capitalization ($150.83 B vs $1.55 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | TSHA | GILD |
|---|---|---|
| Market cap | $1.55 B | $150.83 B |
| US-listed rank | #2293 | #99 |
| Revenue (latest FY) | $9.77M | $29.44B |
| Net income (latest FY) | -$109.00M | $8.51B |
| Net margin | -1115.3% | 28.9% |
| P/E (trailing FY) | - | 17.7 |
| SEC filings | 386 | 981 |
GILEAD SCIENCES, INC. is 97.2x more valuable than Taysha Gene Therapies, Inc. by market capitalization ($150.83 B vs $1.55 B).
In their latest fiscal years, Taysha Gene Therapies, Inc. reported $9.77M in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: Taysha Gene Therapies, Inc. and GILEAD SCIENCES, INC., or browse the full rankings.